Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Researchers study link between cognitive impairment and adherence problems among HF patients

Surviving heart failure calls for lifestyle changes, taking medications and following doctor's orders. Some of the 5 million heart failure patients have trouble adhering to these changes and end up returning to the hospital.

10 May 2010

Kent State University receives four-year, $2.7M grant to study cognitive status of heart failure patients

The National Institutes of Health has awarded a $2.7-million grant to Kent State University for a collaborative research project with Case Western Reserve University School of Nursing, Summa Health System in Akron and University Hospitals Case Medical Center in Cleveland to study cognitive impairment in heart failure patients.

7 May 2010

CardioMEMS completes $37.9M financing

CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.

7 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Study: Hospital follow up can curb readmission rate for heart patients

"Hospitals can slow the revolving door that shuttles heart failure patients back into bed within a month of going home by following up promptly to ensure patients get the right outpatient care, a study shows," USA Today reports.

6 May 2010

Study finds early follow-up for heart failure patients reduces readmission rates

Hospitals that have a higher rate of following up within one week for patients who were discharged after treatment for heart failure have a lower rate of readmission at 30 days for these patients, according to a study in the May 5 issue of JAMA.

5 May 2010

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

Palatin Technologies, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors.

5 May 2010

HHS announces $16M award for Geisinger to create Keystone Beacon Community

Today the Department of Health and Human Services announced that Geisinger Health System will receive $16 million to create the Keystone Beacon Community as part of HHS's Beacon Community cooperative program.

5 May 2010

Response Biomedical first-quarter total revenue down 43%

Response Biomedical Corporation today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Lung researchers at Johns Hopkins have identified a possible protein trigger responsible for sarcoidosis, a potentially fatal inflammatory disease marked by tiny clumps of inflammatory cells that each year leave deep, grainy scars on the lungs, lymph nodes, skin and almost all major organs in hundreds of thousands of Americans.

4 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

Rush Center for Urban Health Equity to focus on disparities in heart and lung disease

Rush University Medical Center has been awarded a $10 million grant from the National Institutes of Health to establish the Rush Center for Urban Health Equity. The aim of the Center is to find ways to promote changes to eliminate the disparities in heart and lung disease affecting inner city residents, in particular those who are low-income persons of color.

4 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

EHR with controlled interventions can produce optimal BP control, reduce mortality

Electronic health records with controlled interventions can produce optimal blood pressure control and reduce mortality, according to data presented at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010).

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

New health law will penalize hospitals for poor quality

The new health law puts the nation's hospitals on strict notice. Either they improve the safety and quality of care for patients or the government will hit them where it hurts the most -- their revenue.

30 Apr 2010

Heart Failure News and Research

Further Reading

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Researchers study link between cognitive impairment and adherence problems among HF patients

Kent State University receives four-year, $2.7M grant to study cognitive status of heart failure patients

CardioMEMS completes $37.9M financing

Cytori Therapeutics to initiate European medical device approval study for Celution System

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

RayBiotech announces biomarker grant winners

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Study: Hospital follow up can curb readmission rate for heart patients

Study finds early follow-up for heart failure patients reduces readmission rates

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

HHS announces $16M award for Geisinger to create Keystone Beacon Community

Response Biomedical first-quarter total revenue down 43%

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Rush Center for Urban Health Equity to focus on disparities in heart and lung disease

BioTime acquires ES Cell International

EHR with controlled interventions can produce optimal BP control, reduce mortality

VIMOVO delayed-release tablets receive FDA approval

New health law will penalize hospitals for poor quality

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News